Litcius/Paper detail

Using probe electrospray ionization mass spectrometry and machine learning for detecting pancreatic cancer with high performance.

Wen Yuan Chung, Elon Correa, Kentaro Yoshimura, Ming‐Chu Chang, Ashley R. Dennison, Sén Takeda, Yu‐Ting Chang

2020PubMed22 citationsOpen Access PDF

Abstract

A rapid blood-based diagnostic modality to detect pancreatic ductal adenocarcinoma (PDAC) with high accuracy is an unmet medical need. The study aimed to validate a unique diagnosis system using Probe Electrospray Ionization Mass Spectrometry (PESI-MS) and Machine Learning to the diagnosis of PDAC. Peripheral blood samples were collected from a total of 322 consecutive PDAC patients and 265 controls with a family history of PDAC. Five µl of serum samples were analyzed using PESI-MS system. The mass spectra from each specimen were then fed into machine learning algorithms to discriminate between control and cancer cases. A total of 587 serum samples were analyzed. The sensitivity of the machine learning algorithm using PESI-MS profiles to identify PDAC is 90.8% with specificity of 91.7% (95% CI 83.9%-97.4% and 82.8%-97.7% respectively). Combined PESI-MS profiles with age and CA19-9 as predictors, the accuracy for stage 1 or 2 of PDAC is 92.9% and for stage 3 or 4 is 93% (95% CI 86.3-98.2; 87.9-97.4 respectively). The accuracy and simplicity of the PESI-MS profiles combined with machine learning provide an opportunity to detect PDAC at an early stage and must be applicable to the examination of at-risk populations.

Topics & Concepts

Pancreatic cancerElectrospray ionizationStage (stratigraphy)MedicineMass spectrometryPancreatic ductal adenocarcinomaInternal medicineCancerChemistryChromatographyBiologyPaleontologyArtificial Intelligence in HealthcarePancreatic and Hepatic Oncology ResearchBlood transfusion and management